Drug-related problems and clinical risk factors relationship in hepatic cirrhosis patients
Diffusion processes in hepatic cirrhosis is characterized with fibrosis and structural changed. Patients with cirrhosis are at risk to get problems because of the effects of the drugs used have drug-related problems (DRPs), due to changes in heart function that affects many aspects of drug pharmacokinetics. Therefore, treatment of patient with hepatic cirrhosis should consider the drug and dose adjustment so that subsequent problems could be avoided. The research method was prospective and descriptive, with a purposive sampling technique. Patients’s treatment were monitoring and analyzed. Significance of 0000 means that p (0000) <0.05, then the Pearson correlation test results are H1a, ie there was a relationship between the numberof DRPs events by the total number of clinical risk factors of DRPs in patientswith cirrhosis. Therefore from this relationship could be expected to know the possible risk of DRPs in patients. The increasing number of clinical risk factors DRPs in patients with cirrhosis, indicate thatthe patient should receive a more stringent monitoring of the provision of therapy because the risk of experiencing DRPs more.
Key words: cirrhosis, drug related problems (DRPs), clinical risk factors of DRPs
American Society of Health-System Pharmacists, 1996, ASHP Guidelines on a Standardized Method for Pharmaceutical Care, Am J Health-Syst Pharm, 53, 1713–6.
Anand, B.S., 1999, Cirrhosis of Liver, Western Journal of Medicine, 171.
Baver, L., 2006, Drug Dosing in Special Populations, Clinical Pharmacokinetics Handbook, McGrawwHill,United States, 39-41.
Blix, H., Vitkil, K., Asmund, R., Tron, M., Bodil, H., Piia,P., Vraalsen T.F., and Walset, E.K., 2004,The Majority of Hospitalised Patients Have Drug-Related Problems: Result from A Prospective Study in General Hospitals, European Journal of Clinical Pharmacology, 60, 9.
Bootman, L., 2007, Drug Related Morbidity and Mortality Impact of Pharmaceutical Care, World Health Organization: Essensial Medicines and Policy Department (EDM): International Conferences on Improving Use of Medicines(ICIUM).
Chan, T., and Critcley, J., 2006, Drug-Related Problems as cause of Hospital Admissions in Hong Kong, Pharmacoepidemiology and Drug Safety, 4, 165-170.
Chung, R.T., and Podolsky, D.K., 2005, Cirrhosis And Alcoholic Liver Disease, Dalam Kasper, D., Braunwald, E., Fauci, A., Hauser, S., Harrison’s Manual of Medicine, 16th ed, McGrawHill Medical Publishing Division, United States, 766-767.
Cipolle, R., Strand, L., and Morney, P., 1998, Pharmaceutical Care Practice, McGrawHill, US, 76-80.
Corelli, R.L., Kradjan, W.A., Koda-Kimble, M.A., Young, L.Y., Guglielmo, B.J., and Alldredge, B.K., 2005, Assessment of Therapy and Pharmaceutical Care, Applied Therapeutics: The Clinical Use of Drugs, 8th ed, Lippincortt Williams & Wilkins, Philadelphia, 1.1-1.21.
Gines, P., Cardenas, A., Arroyo, V., and Rodes, J.,2004, Management of Cirrhosis and Ascites, The New England Journal of Medicine, 350, 9.
Heidelbough, J., and Sherbondy, M., 2006, Cirrhosis and Chronic Liver Failure Part II: Complications and Treatment, American Family Physician, 74, 5.
Heidelbough, J., and Bruderly, M., 2006, Cirrhosis and Chronic Liver Failure Part I: Diagnosis and Evaluation, American Family Physician, 74, 5.
Kenward, R., and Tan, CK., 2003, Penggunaan Obat Pada Gangguan Hati, Farmasi Klinis: Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien, PT Elex Media Komputindo, Jakarta, 155-168.
Mann R, Smart R, and Govoni R, 2004, The Epidemiology of Alcoholic Liver Disease, National Institute on Alcohol Abuse and Alcoholism of The National Institutes of Health, (online):, (http://pubs.niaaa.nih.gov/publications/arh27-3/209-219.htm, diakses 17 September 2010).
McNeely, M., 2004, Case Study: Diabetes in a Patient With Cirrhosis, Clinical Diabetes Journal, 22.
Mill, F.V., 2005, Drug-related Problems: A Cornerstone for Pharmaceutical Care, J. of the Malta College of Pharmacy Practice, 10.
Moore, Aithal, 2006, Guidelines on the Management of Ascites in Cirrhosis, GUT Journal, 55.
Murno, B.H., 2001, Statistical Methods for Health Care Research, Lippincott, Philadelphia, 88.
Obrien, J., and Chennubhotla, S., 2005, Treatment of Edema, American Family Physician, 71, 11.
Samonakis, D.N., Triantos, C.K., Thalheimer, U., Patch, D.W., and Burroughs, A.K., 2004, Management of Portal Hypertension, Postgrad. Med J,80, 634-641.
Sherlock, S., and Dooley, J., 1997, Disease of The Liver and Biliary System, 10th ed, Blackwell Science,
Viktil, K., Blix, H., Moger, T., and Reikvam, A., 2006, Polypharmacy as Commonly Defined is an Indicator of Limited Value in the Assessment of Drug-Related Problems, British Journal of Clinical Pharmacology, 63, 187-195.
Wolf, D., 2007, Cirrhosis, Emedicine, (online):, (http://www.emedicine.com/med/topic3183.htm, diakses 11 September 2010).
Timm, E., and Stragand, J., 2005, Portal Hypertension and Cirrhosis, Pharmacotherapy: A Pathophysiologic Approach, 6th ed, McGrawHill, United States, 693-709.
- There are currently no refbacks.
Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Indonesian J Pharm indexed by:
View My Stats